慢性HBV感染者血清GP73水平与白细胞介素6含量的相关性

摘要/Abstract

摘要： 目的观察慢性乙型肝炎病毒(HBV)感染者血清高尔基体蛋白73(GP73)水平与白细胞介素6(IL-6)含量的变化,探讨血清GP73水平与IL-6含量的相关性。方法选取2015年3月至2016年4月在解放军第一八〇医院住院的慢性HBV感染者268例,其中慢性乙型肝炎(CHB)139例,乙型肝炎肝硬化(HLC)58例,HBV相关肝细胞癌(HCC)71例。选择同期健康体检者50名作为对照组。采用ELISA法检测血清GP73浓度,采用电化学发光法检测血清IL-6含量。结果慢性HBV感染者血清GP73水平显著高于对照组(F=68.61,P<0.001),且随着病情的进展,血清GP73浓度在CHB(111.96±73.02 ng/mL)、HLC(190.86±89.83 ng/mL)和HCC(228.58±114.45 ng/mL)中持续升高,HLC和HCC患者中血清GP73浓度均显著高于CHB,差异有统计学意义(P<0.001)。经过相关性分析,血清GP73含量与慢性HBV感染者病情严重程度呈正相关(r=0.669,P<0.001)。慢性HBV感染者血清IL-6含量显著高于对照组(F=39.94,P<0.001),且随着病情的进展,血清IL-6含量在CHB(3.52±4.85 ng/mL)、HLC(23.42±34.65 ng/mL)和HCC(38.81±40.85 ng/mL)中持续升高,各组间比较,差异有统计学意义(P<0.001)。经过相关性分析,血清IL-6含量与慢性HBV感染者病情的严重程度呈正相关(r=0.500,P<0.001),慢性HBV感染者血清IL-6含量与GP73水平呈正相关(r=0.548,P<0.001)。结论血清GP73水平和IL-6含量与慢性HBV感染者疾病进展密切相关,血清GP73水平和IL-6含量可作为评估肝脏炎症损伤程度的一个重要指标。血清IL-6含量与GP73水平呈正相关,血清IL-6可能参与调节GP73的表达。

许正锯, 潘兴南, 魏梅娟, 刘理冠, 杨环文, 刘钎, 黄志杰. 慢性HBV感染者血清GP73水平与白细胞介素6含量的相关性[J]. 肝脏, 2017, 22(2): 136-138.

参考文献

[1] European Association For The Study of The Liver.EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012,57:167-185.
[2] Marrero J A, Romano P R, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol,2005,43:1007-1012.
[3] Iftikhar R, Kladney R D, Havlioglu N, et al. Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol,2004,99:1087-1095.
[4] Liu X, Wan X, Li Z, et al. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med,2011,49:1311-1316.
[5] Wei H, Li B, Zhang R, et al. Serum GP73, a marker for evaluating progression in patients with chronic HBV infections. PLoS One,2013,8:e53862.
[6] Xu Z, Pan X, Wei K, et al. Serum Golgi protein 73 levels and liver pathological grading in cases of chronic hepatitis B. Mol Med Rep,2015,11:2644-2652.
[7] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版). 中华肝脏病杂志,2011,19:13-24.
[8] 中华人民共和国卫生部(卫办医政发[2011]121号). 原发性肝癌诊疗规范(2011年版). 临床肿瘤学杂志,2011,16:929-946.
[9] Hu JS, Wu DW, Liang S, et al. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol,2010,27:339-345.
[10] Sun Y, Yang H, Mao Y, et al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol,2011,26:1207-1212.
[11] Riener MO, Stenner F, Liewen H, et al. Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas. Hepatology,2009,50:326.
[12] Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut,2010,59:1687-1693.
[13] Xu Z, Liu L, Pan X, et al. Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease. Medicine (Baltimore),2015,94:e659.
[14] Maitra A, Thuluvath PJ. GP73 and liver disease: a (Golgi) complex enigma. Am J Gastroenterol,2004,99:1096-1098.
[15] Kladney RD, Bulla GA, Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene,2000,249:53-65.
[16] Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest,2003,112:978-980.
[17] Liang H, Block T M, Wang M, et al. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark,2012,11:161-171.
[18] Tang QF, Ji Q, Tang Y, et al. Golgi phosphoprotein 2 down-regulates the Th1 response in human gastric cancer cells by suppressing IL-12A. Asian Pac J Cancer Prev,2013,14: 5747-5751.